SEARCH

SEARCH BY CITATION

References

  • 1
    Hasegawa A, Ohtsubo K, Mori W. Pineal gland in old age; quantitative and qualitative morphological study of 168 human autopsy cases. Brain Res 1987; 409: 343349.
  • 2
    Swaab DF. The human hypothalamus basic and clinical aspects. In: Handbook of clinical neurology, Vol 79: 63123. AminoffMJ, FranpcoisB, SwaabDF series eds. Elsevier, Amsterdam, 2003.
  • 3
    Buijs RM, Kalsbeek A. Hypothalamic integration of central and peripheral clocks. Nat Rev Neurosci 2001; 2: 521526.
  • 4
    Arendt J. Melatonin and the Mammalian Pineal Gland. Chapman & Hall, London, 1995.
  • 5
    Dai J, Swaab DF, Buijs RM. Distribution of vasopressin and vasoactive intestinal polypeptide (VIP) fibers in the human hypothalamus with special emphasis on suprachiasmatic nucleus efferent projections. J Comp Neurol 1997; 383: 397414.
  • 6
    Dai J, Swaab DF, Van der Vliet J et al. Postmortem tracing reveals the organization of hypothalamic projections of the suprachiasmatic nucleus in the human brain. J Comp Neurol 1998; 400: 87102.
  • 7
    Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia 1993; 49: 654664.
  • 8
    Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12: 151180.
  • 9
    Klein DC, Coon SL, Roseboom PH et al. The melatonin rhythm-generating enzyme: molecular regulation of serotonin N-acetyltransferase in the pineal gland. Rec Prog Horm Res 1997; 52: 307357; discussion 357–308.
  • 10
    Coon SL, Del Olmo E, Young WS III et al. Melatonin synthesis enzymes in Macaca mulatta: focus on arylalkylamine N-acetyltransferase (EC 2.3.1.87). J Clin Endocrinol Metab 2002; 87: 46994706.
  • 11
    Wu YH, Feenstra MG, Zhou JN et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003; 88: 58985906.
  • 12
    Dai J, Van der Vliet J, Swaab DF et al. Human retinohypothalamic tract as revealed by in vitro postmortem tracing. J Comp Neurol 1998; 397: 357370.
  • 13
    Kalsbeek A, Drijfhout WJ, Westerink BH et al. GABA receptors in the region of the dorsomedial hypothalamus of rats are implicated in the control of melatonin and corticosterone release. Neuroendocrinology 1996; 63: 6978.
  • 14
    Teclemariam-Mesbah R, Ter Horst GJ, Postema F et al. Anatomical demonstration of the suprachiasmatic nucleus-pineal pathway. J Comp Neurol 1999; 406: 171182.
  • 15
    Lockley SW, Skene DJ, Tabandeh H et al. Relationship between napping and melatonin in the blind. J Biol Rhythms 1997; 12: 1625.
  • 16
    Skene DJ, Lockley SW, James K et al. Correlation between urinary cortisol and 6-sulphatoxymelatonin rhythms in field studies of blind subjects. Clin Endocrinol (Oxf) 1999; 50: 715719.
  • 17
    Karasek M, Stankiewicz A, Bandurska-Stankiewicz E et al. Melatonin concentrations in patients with large goiter before and after surgery. Neuroendocrinol Lett 2000; 21: 437439.
  • 18
    Bruce J, Tamarkin L, Riedel C et al. Sequential cerebrospinal fluid and plasma sampling in humans: 24-hour melatonin measurements in normal subjects and after peripheral sympathectomy. J Clin Endocrinol Metab 1991; 72: 819823.
  • 19
    Oxenkrug GF, Anderson GF, Dragovic L et al. Circadian rhythms of human pineal melatonin, related indoles, and beta adrenoreceptors: post-mortem evaluation. J Pineal Res 1990; 9: 111.
  • 20
    Mayeda A, Mannon S, Hofstetter J et al. Effects of indirect light and propranolol on melatonin levels in normal human subjects. Psychiatry Res 1998; 81: 917.
  • 21
    Stoschitzky K, Sakotnik A, Lercher P et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 1999; 55: 111115.
  • 22
    Liu C, Weaver DR, Jin X et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997; 19: 91102.
  • 23
    Arendt J, Skene DJ, Middleton B et al. Efficacy of melatonin treatment in jet lag, shift work, and blindness. J Biol Rhythms 1997; 12: 604617.
  • 24
    Sack RL, Brandes RW, Kendall AR et al. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med 2000; 343: 10701077.
  • 25
    Skene DJ. Optimization of light and melatonin to phase-shift human circadian rhythms. J Neuroendocrinol 2003; 15: 438441.
  • 26
    Fischer S, Smolnik R, Herms M et al. Melatonin acutely improves the neuroendocrine architecture of sleep in blind individuals. J Clin Endocrinol Metab 2003; 88: 53155320.
  • 27
    Allegra M, Reiter RJ, Tan DX et al. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003; 34: 110.
  • 28
    Rodriguez C, Mayo JC, Sainz RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 19.
  • 29
    Pappolla MA, Chyan YJ, Poeggeler B et al. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm 2000; 107: 203231.
  • 30
    Reiter RJ, Tan DX, Manchester LC et al. Melatonin reduces oxidant damage and promotes mitochondrial respiration: implications for aging. Ann N Y Acad Sci 2002; 959: 238250.
  • 31
    Van Someren EJ, Riemersma RF, Swaab DF. Functional plasticity of the circadian timing system in old age: light exposure. Prog Brain Res 2002; 138: 205231.
  • 32
    Weitzman ED, Moline ML, Czeisler CA et al. Chronobiology of aging: temperature, sleep-wake rhythms and entrainment. Neurobiol Aging 1982; 3: 299309.
  • 33
    Czeisler CA, Duffy JF, Shanahan TL et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science 1999; 284: 21772181.
  • 34
    Mailloux A, Benstaali C, Bogdan A et al. Body temperature and locomotor activity as marker rhythms of aging of the circadian system in rodents. Exp Gerontol 1999; 34: 733740.
  • 35
    Duffy JF, Dijk DJ, Klerman EB et al. Later endogenous circadian temperature nadir relative to an earlier wake time in older people. Am J Physiol 1998; 275: R14781487.
  • 36
    Dijk DJ, Duffy JF, Czeisler CA. Contribution of circadian physiology and sleep homeostasis to age-related changes in human sleep. Chronobiol Int 2000; 17: 285311.
  • 37
    Skene DJ, Swaab DF. Melatonin rhythmicity: effect of age and Alzheimer's disease. Exp Gerontol 2003; 38: 199206.
  • 38
    Luboshitzky R, Yanai D, Shen-Orr Z et al. Daily and seasonal variations in the concentration of melatonin in the human pineal gland. Brain Res Bull 1998; 47: 271276.
  • 39
    Zeitzer JM, Daniels JE, Duffy JF et al. Do plasma melatonin concentrations decline with age? Am J Med 1999; 107: 432436.
  • 40
    Fourtillan JB, Brisson AM, Fourtillan M et al. Melatonin secretion occurs at a constant rate in both young and older men and women. Am J Physiol Endocrinol Metab 2001; 280: E11E22.
  • 41
    Zhou JN, Liu RY, Van Heerikhuize J et al. Alterations in the circadian rhythm of salivary melatonin begin during middle-age. J Pineal Res 2003; 34: 1116.
  • 42
    Kennaway DJ, Lushington K, Dawson D et al. Urinary 6-sulfatoxymelatonin excretion and aging: new results and a critical review of the literature. J Pineal Res 1999; 27: 210220.
  • 43
    Zhao ZY, Xie Y, Fu YR et al. Aging and the circadian rhythm of melatonin: a cross-sectional study of Chinese subjects 30–110 yr of age. Chronobiol Int 2002; 19: 11711182.
  • 44
    Bergiannaki JD, Soldatos CR, Paparrigopoulos TJ et al. Low and high melatonin excretors among healthy individuals. J Pineal Res 1995; 18: 159164.
  • 45
    Kunz D, Schmitz S, Mahlberg R et al. A new concept for melatonin deficit: on pineal calcification and melatonin excretion. Neuropsychopharmacology 1999; 21: 765772.
  • 46
    Duffy JF, Zeitzer JM, Rimmer DW et al. Peak of circadian melatonin rhythm occurs later within the sleep of older subjects. Am J Physiol Endocrinol Metab 2002; 282: E297E303.
  • 47
    Gusek W. Histology of the pineal gland in the elderly human. Aktuelle Gerontol 1983; 13: 111114.
  • 48
    Kunz D, Bes F, Schlattmann P et al. On pineal calcification and its relation to subjective sleep perception: a hypothesis-driven pilot study. Psychiatry Res 1998; 82: 187191.
  • 49
    Schmid HA. Decreased melatonin biosynthesis, calcium flux, pineal gland calcification and aging: a hypothetical framework. Gerontology 1993; 39: 189199.
  • 50
    Bojkowski CJ, Arendt J. Factors influencing urinary 6-sulphatoxymelatonin, a major melatonin metabolite, in normal human subjects. Clin Endocrinol (Oxf) 1990; 33: 435444.
  • 51
    Otani T, Gyorkey F, Farrell G. Enzymes of the human pineal body. J Clin Endocrinol Metab 1968; 28: 349354.
  • 52
    Tapp E, Huxley M. The histological appearance of the human pineal gland from puberty to old age. J Pathol 1972; 108: 137144.
  • 53
    Pardo CA, Martin LJ, Troncoso JC et al. The human pineal gland in aging and Alzheimer's disease: patterns of cytoskeletal antigen immunoreactivity. Acta Neuropathol (Berl) 1990; 80: 535540.
  • 54
    Arieti S. The pineal gland in old age. J Neuropathol Exp Neurol 1954; 13: 482491.
  • 55
    Jengeleski CA, Powers RE, O'Connor DT et al. Noradrenergic innervation of human pineal gland: abnormalities in aging and Alzheimer's disease. Brain Res 1989; 481: 378382.
  • 56
    Hofman MA, Swaab DF. Alterations in circadian rhythmicity of the vasopressin-producing neurons of the human suprachiasmatic nucleus (SCN) with aging. Brain Res 1994; 651: 134142.
  • 57
    Hofman MA, Swaab DF. Influence of aging on the seasonal rhythm of the vasopressin-expressing neurons in the human suprachiasmatic nucleus. Neurobiol Aging 1995; 16: 965971.
  • 58
    Hofman MA. The human circadian clock and aging. Chronobiol Int 2000; 17: 245259.
  • 59
    Swaab DF, Fliers E, Partiman TS. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res 1985; 342: 3744.
  • 60
    Shochat T, Martin J, Marler M et al. Illumination levels in nursing home patients: effects on sleep and activity rhythms. J Sleep Res 2000; 9: 373379.
  • 61
    Mishima K, Okawa M, Shimizu T et al. Diminished melatonin secretion in the elderly caused by insufficient environmental illumination. J Clin Endocrinol Metab 2001; 86: 129134.
  • 62
    van Someren EJ, Hagebeuk EE, Lijzenga C et al. Circadian rest–activity rhythm disturbances in Alzheimer's disease. Biol Psychiatry 1996; 40: 259270.
  • 63
    Charman WN. Age, lens transmittance, and the possible effects of light on melatonin suppression. Ophthalmic Physiol Opt 2003; 23: 181187.
  • 64
    Klerman EB, Duffy JF, Dijk DJ et al. Circadian phase resetting in older people by ocular bright light exposure. J Investig Med 2001; 49: 3040.
  • 65
    Mirmiran M, Swaab DF, Kok JH et al. Circadian rhythms and the suprachiasmatic nucleus in perinatal development, aging and Alzheimer's disease. Prog Brain Res 1992; 93: 151162; discussion 162–163.
  • 66
    Ancoli-Israel S, Klauber MR, Jones DW et al. Variations in circadian rhythms of activity, sleep, and light exposure related to dementia in nursing-home patients. Sleep 1997; 20: 1823.
  • 67
    Werth E, Savaskan E, Knoblauch V et al. Decline in long-term circadian rest–activity cycle organization in a patient with dementia. J Geriatr Psychiatry Neurol 2002; 15: 5559.
  • 68
    Martin J, Marler M, Shochat T et al. Circadian rhythms of agitation in institutionalized patients with Alzheimer's disease. Chronobiol Int 2000; 17: 405418.
  • 69
    Moe KE, Vitiello MV, Larsen LH et al. Symposium: Cognitive processes and sleep disturbances: sleep/wake patterns in Alzheimer's disease: relationships with cognition and function. J Sleep Res 1995; 4: 1520.
  • 70
    Pollak CP, Perlick D. Sleep problems and institutionalization of the elderly. J Geriatr Psychiatry Neurol 1991; 4: 204210.
  • 71
    van Someren EJ, Mirmiran M, Swaab DF. Non-pharmacological treatment of sleep and wake disturbances in aging and Alzheimer's disease: chronobiological perspectives. Behav Brain Res 1993; 57: 235253.
  • 72
    Burney-Puckett M. Sundown syndrome: etiology and management. J Psychosoc Nurs Ment Health Serv 1996; 34: 4043.
  • 73
    Wirz-Justice A, Werth E, Savaskan E et al. Haloperidol disrupts, clozapine reinstates the circadian rest–activity cycle in a patient with early-onset Alzheimer disease. Alzheimer Dis Assoc Disord 2000; 14: 212215.
  • 74
    Magri F, Locatelli M, Balza G et al. Changes in endocrine circadian rhythms as markers of physiological and pathological brain aging. Chronobiol Int 1997; 14: 385396.
  • 75
    Ferrari E, Arcaini A, Gornati R et al. Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. Exp Gerontol 2000; 35: 12391250.
  • 76
    Ohashi Y, Okamoto N, Uchida K et al. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type. Biol Psychiatry 1999; 45: 16461652.
  • 77
    Mishima K, Tozawa T, Satoh K et al. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep–waking. Biol Psychiatry 1999; 45: 417421.
  • 78
    Skene DJ, Vivien-Roels B, Sparks DL et al. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease. Brain Res 1990; 528: 170174.
  • 79
    Uchida K, Okamoto N, Ohara K et al. Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brain Res 1996; 717: 154159.
  • 80
    Liu RY, Zhou JN, van Heerikhuize J et al. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 1999; 84: 323327.
  • 81
    Zhou JN, Liu RY, Kamphorst W et al. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003; 35: 125130.
  • 82
    Rousseau A, Petren S, Plannthin J et al. Serum and cerebrospinal fluid concentrations of melatonin: a pilot study in healthy male volunteers. J Neural Transm 1999; 106: 883888.
  • 83
    Matsubara E, Bryant-Thomas T, Pacheco Quinto J et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 2003; 85: 11011108.
  • 84
    Friedland RP, Luxenberg JS, Koss E. A quantitative study of intracranial calcification in dementia of the Alzheimer type. Int Psychogeriatr 1990; 2: 3643.
  • 85
    Sparks DL, Woeltz VM, Markesbery WR. Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease. Arch Neurol 1991; 48: 718721.
  • 86
    Sherif F, Gottfries CG, Alafuzoff I et al. Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1992; 4: 227240.
  • 87
    Emilsson L, Saetre P, Balciuniene J et al. Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer's disease patients. Neurosci Lett 2002; 326: 5660.
  • 88
    Takehashi M, Tanaka S, Masliah E et al. Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant. Neurosci Lett 2002; 327: 7982.
  • 89
    Zhou JN, Hofman MA, Swaab DF. VIP neurons in the human SCN in relation to sex, age, and Alzheimer's disease. Neurobiol Aging 1995; 16: 571576.
  • 90
    Liu RY, Zhou JN, Hoogendijk WJ et al. Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression. J Neuropathol Exp Neurol 2000; 59: 314322.
  • 91
    Swaab DF, Grundke-Iqbal I, Iqbal K et al. Tau and ubiquitin in the human hypothalamus in aging and Alzheimer's disease. Brain Res 1992; 590: 239249.
  • 92
    van de Nes JA, Kamphorst W, Ravid R et al. The distribution of Alz-50 immunoreactivity in the hypothalamus and adjoining areas of Alzheimer's disease patients. Brain 1993; 116(Pt 1):103115.
  • 93
    van de Nes JA, Kamphorst W, Ravid R et al. Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathol (Berl) 1998; 96: 129138.
  • 94
    Stopa EG, Volicer L, Kuo-Leblanc V et al. Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol 1999; 58: 2939.
  • 95
    Campbell SS, Kripke DF, Gillin JC et al. Exposure to light in healthy elderly subjects and Alzheimer's patients. Physiol Behav 1988; 42: 141144.
  • 96
    Blanks JC, Torigoe Y, Hinton DR et al. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging 1996; 17: 377384.
  • 97
    Blanks JC, Schmidt SY, Torigoe Y et al. Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging 1996; 17: 385395.
  • 98
    Klaver CC, Ott A, Hofman A et al. Is age-related maculopathy associated with Alzheimer's Disease? The Rotterdam Study. Am J Epidemiol 1999; 150: 963968.
  • 99
    Bayer AU, Ferrari F. Severe progression of glaucomatous optic neuropathy in patients with Alzheimer's disease. Eye 2002; 16: 209212.
  • 100
    Curcio CA, Drucker DN. Retinal ganglion cells in Alzheimer's disease and aging. Ann Neurol 1993; 33: 248257.
  • 101
    Davies DC, McCoubrie P, McDonald B et al. Myelinated axon number in the optic nerve is unaffected by Alzheimer's disease. Br J Ophthalmol 1995; 79: 596600.
  • 102
    Justino L, Kergoat M, Bergman H et al. Neuroretinal function is normal in early dementia of the Alzheimer type. Neurobiol Aging 2001; 22: 691695.
  • 103
    Cohen-Mansfield J, Garfinkel D, Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia – a preliminary study. Arch Gerontol Geriatr 2000; 31: 6576.
  • 104
    Brusco LI, Marquez M, Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol Lett 2000; 21: 3942.
  • 105
    Brusco LI, Marquez M, Cardinali DP. Monozygotic twins with Alzheimer's disease treated with melatonin: case report. J Pineal Res 1998; 25: 260263.
  • 106
    Jean-Louis G, von Gizycki H, Zizi F. Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. J Pineal Res 1998; 25: 177183.
  • 107
    Cardinali DP, Brusco LI, Liberczuk C et al. REVIEW. The use of melatonin in Alzheimer's disease. Neuroendocrinol Lett 2002; 23(Suppl. 1):2023.
  • 108
    Singer C, Tractenberg RE, Kaye J et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003; 26: 893901.
  • 109
    Serfaty M, Kennell-Webb S, Warner J et al. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry 2002; 17: 11201127.
  • 110
    Kobayashi R, Kohsaka M, Fukuda N et al. Effects of morning bright light on sleep in healthy elderly women. Psychiatry Clin Neurosci 1999; 53: 237238.
  • 111
    Van Someren EJ, Kessler A, Mirmiran M et al. Indirect bright light improves circadian rest–activity rhythm disturbances in demented patients. Biol Psychiatry 1997; 41: 955963.
  • 112
    Yamadera H, Ito T, Suzuki H et al. Effects of bright light on cognitive and sleep-wake (circadian) rhythm disturbances in Alzheimer-type dementia. Psychiatry Clin Neurosci 2000; 54: 352353.
  • 113
    Graf A, Wallner C, Schubert V et al. The effects of light therapy on mini-mental state examination scores in demented patients. Biol Psychiatry 2001; 50: 725727.
  • 114
    Mishima K, Hishikawa Y, Okawa M. Randomized, dim light controlled, crossover test of morning bright light therapy for rest–activity rhythm disorders in patients with vascular dementia and dementia of Alzheimer's type. Chronobiol Int 1998; 15: 647654.
  • 115
    Van Someren EJ, Lijzenga C, Mirmiran M et al. Long-term fitness training improves the circadian rest–activity rhythm in healthy elderly males. J Biol Rhythms 1997; 12: 146156.
  • 116
    Van Someren EJ, Scherder EJ, Swaab DF. Transcutaneous electrical nerve stimulation (TENS) improves circadian rhythm disturbances in Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 114118.
  • 117
    Scherder EJ, Van Someren EJ, Swaab DF. Transcutaneous electrical nerve stimulation (TENS) improves the rest–activity rhythm in midstage Alzheimer's disease. Behav Brain Res 1999; 101: 105107.